- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01360190
Neurophysiologic Monitoring of Antidepressant Treatment (Lilly)
Study Overview
Detailed Description
Background and Significance/Preliminary Studies:
A. Cordance. There is considerable evidence indicating that abnormal slow-wave activity in the EEG is caused by partial cortical deafferentation. Despite this fact, no clinically relevant measure of deafferentation has been available. The investigators sought to develop such a measure by examining young and old subjects with white-matter lesions that presumably undercut the cerebral cortex, as well as subjects with several different types of brain disease who had undergone SPECT scanning. The investigators discovered an indicator termed discordance, that is characteristic of cortex undercut by white-matter lesions, or that is hypoperfused for any reason. The investigators also discovered an indicator the investigators termed concordance , which is characteristic of cortex that has normal perfusion.
This overall technique for the non-invasive assessment of afferent function, cerebral perfusion, and metabolism the investigators call cordance mapping, which is the subject of a United States patent. A detailed explanation of the formulae used to calculate cordance is provided in the manuscripts referenced above. The first of these two manuscripts contains illustrative examples where discordance was useful in detection of white-matter lesions or degenerative disease. The second manuscript shows a quantitative analysis of cordance and HMPAO-SPECT data from 27 patients with a variety of conditions, and demonstrates that cordance is superior to conventional EEG measures in its correlations with relative perfusion. Like SPECT, cordance measurements vary according to the patients' state, but has high test-retest reliability for detecting brain lesions.
B. Differential diagnosis of depression. One promising application of cordance is to the differential diagnosis of psychiatric illness. A "normal" cordance pattern is one of posterior dominant concordance with cordance values near zero in the frontal regions. The investigators have reported a "classic" cordance pattern for subjects with Alzheimer's disease (DAT), in which there is parietal discordance (in the beta or theta bands) in conjunction with alpha concordance that has shifted from the occipital to the central head regions. This finding is consistent with the pattern seen commonly on PET and SPECT, in which there is parietal hypoperfusion or hypometabolism with preserved metabolism over the central head regions (the motor strip), which is known to be less affected by Alzheimer's changes.
In evaluating treatment results, the investigators will need to determine what effect medication status has upon QEEG measures. Although results thus far suggest that there is little significant effect , the investigators will carefully examine the effects of antidepressant and antianxiety medications further
METHODS:
The investigators plan to examine cordance in 26 subjects undergoing antidepressant treatment, and to use this neurophysiologic method to assess the response to treatment in depressed patients. The project has the following three specific aims: 1) to identify physiologic indices of fluoxetine treatment response using quantitative EEG; 2) to detect how early in the course of fluoxetine treatment response this response may be detected; 3) to determine if QEEG measures of response distinguish subjects who are not responding to treatment from those who are responding.
The study will tests the hypothesis that those subjects receiving active treatment who show clinical improvement will demonstrate normalization of cordance maps. Conversely, the investigators hypothesize that those subjects who either do not show improvement, or who have some improvement on placebo, will not show normalization of cordance.
The investigators will examine these hypotheses with a four-step plan. Specifically, the investigators will recruit 26 patients with major depression and perform baseline assessments of the severity of depressive symptoms, as well as QEEG studies. Second, the investigators will enroll these patients in an eight-week, double-blind placebo-controlled study in which they will receive either fluoxetine 20 mg. daily or placebo. Third, the investigators will follow subjects with ratings of mood and serial QEEG studies to determine if there is an association between resolution of depressive symptoms and QEEG cordance changes. Fourth, the investigators will enroll subjects in open-label treatment at the end of the eight weeks and examine cordance in those who previously received placebo and, where appropriate, in those receiving fluoxetine 40 mg. daily.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- All subjects will meet DSM-IV criteria for major depression based upon the Structured Clinical Interview for DSM-IV - Patient Version (SCID-P) (First et al., 1994). All research personnel have undergone SCID-P training, and soon will extend this training to the DSM-IV version.
- Subjects also will have a score on the 17-item Hamilton Depression Rating Scale of > 18 (with item #1 > 2).
- All subjects will be under the care of a clinician not affiliated with the study at the time of entry into the study, and through the course of the study.
Exclusion Criteria:
- Subjects will have no serious medical illness.
- We will exclude patients also meeting criteria for the following groups of axis I diagnoses: delirium or dementia, substance-related disorders, schizophrenia or other psychotic disorders, or eating disorders.
- In addition, patients meeting criteria for cluster A or B axis II diagnoses will be excluded.
- Subjects with a history of current or past active suicidal ideation, or suicide attempts will be excluded, as will patients who previously have failed to respond to an adequate clinical trial of fluoxetine, or have failed to tolerate the medication.
- Subjects who have had suboptimal trials, however, may still be considered for the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: placebo
|
fluoxetine 20 mg. daily
|
Active Comparator: fluoxetine
|
fluoxetine 20 mg. daily
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Hamilton Rating Scale For Depression Score
Time Frame: baseline, end of placebo-lead-in; and 48 hours, 1 week, 2 weeks, 4 weeks, and 8 weeks after randomized treatment
|
We will determine which subjects demonstrate improvement on the primary outcome measure (Ham-D) obtained the day of the EEG, and enter these as categorical variables (improved/not improved).
|
baseline, end of placebo-lead-in; and 48 hours, 1 week, 2 weeks, 4 weeks, and 8 weeks after randomized treatment
|
Collaborators and Investigators
Investigators
- Principal Investigator: Andrew F Leuchter, University of California, Los Angeles
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Behavioral Symptoms
- Mental Disorders
- Mood Disorders
- Depression
- Depressive Disorder
- Depressive Disorder, Major
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Psychotropic Drugs
- Serotonin Uptake Inhibitors
- Neurotransmitter Uptake Inhibitors
- Membrane Transport Modulators
- Serotonin Agents
- Antidepressive Agents
- Cytochrome P-450 Enzyme Inhibitors
- Antidepressive Agents, Second-Generation
- Cytochrome P-450 CYP2D6 Inhibitors
- Fluoxetine
Other Study ID Numbers
- 94-08-273-13
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Major Depressive Disorder
-
York UniversityCentre for Addiction and Mental HealthSuspendedDisorder, Major DepressiveCanada
-
Shalvata Mental Health CenterUnknownMAjor Depressive DisorderIsrael
-
Seasons Biotechnology (Taizhou) Co., Ltd.CompletedMajor Depressive Disorder (MDD)India
-
Repurposed Therapeutics, Inc.Unknown
-
GlaxoSmithKlineCompletedMajor Depressive Disorder (MDD)United States
-
Seasons Biotechnology (Taizhou) Co., Ltd.CompletedMajor Depressive Disorder (MDDIndia
-
Gangnam Severance HospitalCompletedMajor Depressive Disorder(MDD)Korea, Republic of
-
University College, LondonCompletedUnipolar Major Depressive DisorderUnited Kingdom
-
Fundació Institut de Recerca de l'Hospital de la...Fondo de Investigacion SanitariaUnknown
-
AccexibleRecruitingMajor Depressive Disorder (MDD)Spain
Clinical Trials on fluoxetine
-
Yale UniversityNational Institute of Mental Health (NIMH)RecruitingObsessive-Compulsive DisorderUnited States
-
Chen QianRecruiting
-
Nanfang Hospital, Southern Medical UniversityRecruiting
-
Fundació Institut de Recerca de l'Hospital de la...Terminated
-
Centre Hospitalier St AnneTerminated
-
Teva Pharmaceuticals USACompleted
-
Teva Pharmaceuticals USACompleted
-
University of Sao PauloNovartis; Fundação de Amparo à Pesquisa do Estado de São Paulo; Conselho Nacional...CompletedObsessive Compulsive DisorderBrazil